Oral BPC-157: what capsules and pills were tested for, and what is missing

The short answer: oral BPC-157 has real animal data behind it, and almost nothing else. In rat studies, BPC-157 given in drinking water helped heal ligaments, bowel, and fistulas, often as well as the injected form. [3] [4] [5] But no study has measured how much of an oral capsule is absorbed in a person, the one registered human trial of oral tablets never posted results, and every product sold as a capsule or pill today is outside any lawful supply chain. [7] [8]

This post covers what the oral and injected forms were actually tested for, the stomach-stability and arginate-salt claims behind the capsule market, and the absorption data that does not exist. It does not give dosing advice; there is no established human dose for BPC-157.

What is oral BPC-157?

BPC-157 is a synthetic chain of 15 amino acids based on a fragment of a protein found in human gastric juice. The research group that discovered it describes it as stable in gastric juice and active when given by mouth as well as by injection. [1] That origin story is the main reason BPC-157 is sold as capsules, tablets, and pills, which most peptides are not: most peptides are broken down by stomach acid and digestive enzymes before they can be absorbed.

In the market, "oral BPC-157" covers several things: capsules of the standard peptide, capsules labeled as the arginate salt, tablets, and more recently gummies. None is an FDA approved product, and none has a published human trial behind it. [7]

Does oral BPC-157 work? What the animal studies used

Most of the oral evidence comes from rats given BPC-157 in their drinking water, usually from the same Zagreb laboratory. The findings are consistent within that literature:

• Ligament. After surgical cutting of the knee's medial collateral ligament, BPC-157 improved functional, biomechanical, and microscopic healing over 90 days whether it was injected, applied as a cream, or given in drinking water. [3]
• Short bowel. In rats with most of the small bowel removed, BPC-157 given by mouth or by injection reversed weight loss and increased villus height and gut wall thickness over 4 weeks. [4]
• Fistula. In a colon-to-skin fistula model, BPC-157 given by injection or in drinking water sped closure of both the colon and skin defects. [5]

The same group's reviews summarize similar oral results for ulcers caused by alcohol and anti-inflammatory drugs, and for colitis. [1] [2] What these studies share is the model: rats drinking dissolved peptide over days or weeks, with outcomes read at autopsy. They show oral activity in rats. They do not show that a human capsule delivers a meaningful amount of peptide, and independent replication outside the originating group is limited. [11]

BPC-157 oral vs injection: what the comparisons show

The head-to-head comparisons that exist are within rat studies, where the oral and injected groups often did about equally well. [3] [4] That is the source of the common claim that "oral works just as well."

The claim does not transfer cleanly to people, for three reasons:

1. Route to the target. In a gut injury model, an oral dose reaches the injured tissue directly. For a knee or a shoulder, the peptide would have to survive digestion and be absorbed into the blood first.
2. Half-life. In the only formal pharmacokinetic study, in rats and dogs, injected BPC-157 had an elimination half-life under 30 minutes and was quickly broken into small fragments and single amino acids. [6] That study tested intravenous and intramuscular dosing only. It did not measure oral absorption.
3. No human numbers. A 2026 review of the drug-development record found that BPC-157's human pharmacokinetics are critically under-characterized, that it lacks basic permeability data, and that no pharmaceutical-grade formulation has been developed or validated. [7]

If you are weighing BPC-157 against the other healing peptide it is usually paired with, our BPC-157 vs TB-500 comparison covers both; neither has human evidence for injury healing.

Is BPC-157 stable in stomach acid?

"Gastric stability" is the core selling point for capsules. The supporting evidence is the discovering group's description of BPC-157 as stable in human gastric juice. [2] A 2026 independent review accepted that BPC-157 shows unusual stability in gastric juice and activity by oral, injected, and topical routes in preclinical work. [7]

Stability is not the same as absorption. A peptide can survive stomach acid and still be poorly absorbed through the intestinal wall, or be broken down by enzymes further along the gut. One research team even engineered lactic acid bacteria as a vehicle to carry BPC-157 to the gut lining, which shows that delivering it by mouth is still treated as an open research problem. [10]

What is BPC-157 arginate salt?

BPC-157 arginate is the arginine salt of the same peptide, marketed as the more stable choice for capsules. Once dissolved, the peptide chain is the same molecule, so it carries the same evidence base: animal only.

We found no peer-reviewed study that compares the arginate salt with the standard form for stability, absorption, or effect, in animals or in people. The 2026 formulation review found no validated formulation of any kind and no formal excipient compatibility studies. [7] Until someone publishes that comparison, "more stable" is a manufacturing claim, not a clinical one.

Has anyone measured oral BPC-157 absorption in people?

No published study has. The closest attempts are registered trials without results:

• Oral tablets in healthy volunteers. A randomized, placebo-controlled phase 1 trial of oral BPC-157 tablets was registered in 2015 to measure safety and pharmacokinetics, with an estimated 42 participants. Its status is listed as unknown and no results have been posted. [8]
• Oral gummies. A single-group study of gummies containing BPC-157 in 40 physically active adults, run by the product's maker, measured inflammation markers and self-reported recovery over 8 weeks. It had no control group and no blinding, and it has not posted results. [9]

Neither can tell you whether a capsule works. The first never reported. The second could not separate the product's effect from placebo, time, or training changes even if it does report.

Are BPC-157 capsules and pills legal?

BPC-157 is not an FDA approved drug in any form. FDA's Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in July 2026, but that recommendation is advisory. [12] Until FDA publishes a final rule, BPC-157 is not on the bulks list and a 503A pharmacy has no federal basis to compound it from bulk, as capsules or as injections. [13] Track the rule on the BPC-157 regulatory timeline, and see the state legal guides for pharmacy board rules.

Capsules and pills sold as research chemicals or supplements are not lawful for human use and are not verified for identity or purity. Contamination and inaccurate content are among the main risks reviewers flag for unregulated peptides. [15] There is no lawful price to compare yet; the BPC-157 cost page explains why. BPC-157 is prohibited at all times for tested athletes, in every form. [14]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers do offer BPC-157, and prescribers write prescriptions for it. That does not make it lawful yet. The July 2026 advisory committee recommendation awaits an FDA final rule, [12] and until then a 503A pharmacy has no federal basis to compound it. [13] FDA has warned a 503A pharmacy that compounded BPC-157 acetate outside section 503A. [19]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, its Category 2 safety list, and import alerts that let it detain peptide shipments, rather than stopping every pharmacy. [17] [18] [19] [20] [21] State boards of pharmacy oversee pharmacies day to day, and their rules differ. [16]

What changes for you:

• No FDA review of the product. FDA does not verify a compounded drug's safety, effectiveness, or quality before it is sold. [16]
• Identity, purity, sterility, and dose accuracy vary; contamination and inaccurate content are among the main risks reviewers flag for unregulated peptides. [15]
• Insurance rarely pays, because there is no approved indication to match, so you usually pay cash.
• Sport. BPC-157 is prohibited at all times on the WADA list. [14]

What to check: a 503A pharmacy licensed in your state, a real evaluation by a licensed prescriber rather than an online form, and a certificate of analysis for the specific batch. These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. No approved drug contains BPC-157.

Where this leaves oral BPC-157

The oral evidence is animal only, mostly from one laboratory, and strongest for gut injury, where an oral dose meets the tissue directly; the inflammatory bowel disease page grades it that way. For tendon and ligament use, see how it ranks on the tendon injury page. If a lawful path opens after the FDA rule, the practical questions will be which forms a pharmacy can compound and how a prescriber decides; our guides to what peptide therapy is and how to get peptides prescribed cover how that works today. The companion posts on BPC-157 human studies and BPC-157 for gut health go deeper on the trial record and the gut literature.